newsfilter
← Latest News
GlobeNewswire·

Paratek Pharmaceuticals Announces Modification of BARDA Contract to Advance the Development of NUZYRA® (omadacycline) for Post-Exposure Prophylaxis (PEP) and Treatment of Pulmonary Anthrax

-- Third procurement to be split into two procurements based on the achievement of specific anthrax development milestones-- Next procurement expected in early 2024 BOSTON, July 10, 2023 (GLOBE NEWSWIRE) -- Paratek